AI filing briefs

TRex Bio, Inc. (TRXB)

TRXB 8-K filings, explained

Every material Form 8-K TRex Bio, Inc. has filed with the SEC since November 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.

Briefs on record1since Nov 13, 2026
Latest filingNov 13, 2026earnings
High impact (4-5)0of 1 brief
ToneNegative1

2026

Nov 13, 4:04 PM ET

TRexBio reports Q3 2026 net loss of $13.2 million; October IPO raised $133.5 million

Negative earnings 2.02

TRexBio, a clinical-stage biotechnology company, reported third quarter 2026 results with a net loss of $13.2 million, up from $7.9 million a year earlier, as research and development and administrative costs rose. The company completed a $133.5 million initial public offering in October 2026, and it expects its cash and IPO proceeds to fund operations into the second half of 2029.

  • Net loss was $13.2 million for Q3 2026, compared with $7.9 million for Q3 2025.
  • R&D expenses were $11.4 million, up from $7.0 million, mainly due to higher clinical trial costs for TRB-061.
  • Cash, cash equivalents and marketable securities were $78.2 million at September 30, 2026, excluding about $119.0 million in IPO net proceeds.
  • Topline Phase 1b data for TRB-061 in atopic dermatitis are expected in mid-2027.
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every TRex Bio, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →